Pharmafile Logo
Pharmafocus logo
Advanced Search

Exviera

Showing 4 posts of 4 posts found.

NICE to recommend three new treatments for hep C

October 16, 2015
Medical Communications AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, Viekirax, daklinza, harvoni, hepatitis C

NICE has recommended Bristol-Myers Squibb’s Daklinza, Gilead’s Harvoni and AbbVie’s Viekirax, with or without Exviera, as treatments for some adults …

News
Daklinza

NICE restricts access to new hepatitis C treatments

July 29, 2015
Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, daklinza, harvoni, hepatits C

NICE has recommended three new treatment options for hepatitis C in draft guidance – but has been criticised for excluding …

News
Abbvie image

AbbVie hep C drug gets priority review in Japan

April 16, 2015
Sales and Marketing AbbVie, EC, EU, Europe, Exviera, FDA, Japan, Viekira Pak, Viekirax, hepatitis C, ombitasvir/paritaprevir/ritonavir

AbbVie’s combination hepatitis C treatment looks set to be approved in yet another country after being granted priority review in …

News
Viekirax and Exviera image

AbbVie Hep C combo pill ready for Europe

January 16, 2015
Medical Communications AbbVie, Exviera, FDA, HIV, Viekira Pak, Viekirax, harvoni, hep C, sovaldi

The European Commission has approved AbbVie’s Viekirax and Exviera for the treatment of chronic hepatitis C (HCV). Viekirax (ombitasvir/paritaprevir/ritonavir) and …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026